Re: Farmas USA
CLSN
BTIG Starts Celsion Corp (CLSN) at Buy, PT $10
Analyst Hartaj Sing said valuation seem "irrational," as he expected positive results from its phase 3 OPTIMA trial.
ThermoDox recently impressed with a 59% survival benefit that is statistically significant in a subset of 285 patients (41% of original HEAT participants)
«Después de nada, o después de todo/ supe que todo no era más que nada.»